Among active 13F managers last quarter, 2 added and none reduced or exited; the largest holder to move was Tower Research Capital LLC (TRC) (+22%). Over the last 180 days, 1 insider bought and none sold, a net +$3K in open-market trades.
Funds lean in and no leg opposes.
24 tracked 13F filers disclose a position in VIVS as of the latest SEC 13F filings, a combined $103K in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 2 funds added to an existing position in VIVS, while none reduced or exited. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Nvidia CorpNVDA | 8 funds | $811.2M |
| Apple IncAAPL | 8 funds | $630.8M |
| Alphabet Inc-CL AGOOGL | 8 funds | $292.2M |
| Amazon.com IncAMZN | 8 funds | $290.4M |
| Micron Technology IncMU | 8 funds | $242.1M |
| Tesla IncTSLA | 8 funds | $223.0M |
| Alphabet Inc-CL CGOOG | 8 funds | $160.5M |
| Advanced Micro DevicesAMD | 8 funds | $133.1M |
| Berkshire Hathaway Inc-CL BBRK/B | 8 funds | $122.2M |
| Applied Materials IncAMAT | 8 funds | $118.6M |
| JPMorgan Chase & CoJPM | 8 funds | $107.0M |
| Eli Lilly & CoLLY | 8 funds | $101.4M |
Ranked by how many of VIVS's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in VIVS.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Lialin Tony Serge | Chief Commercial Officer | Buy (P) | 10K | $3K |
| Nov 17, 2025 | Gobel David | Director | Buy (S) | 3K | $7K |
| Nov 15, 2023 | Gobel David | Director | Sell (S) | 20K | $32K |
| Aug 17, 2021 | Cohen Douglas Jay | Director | Buy (P) 3 lots, same day | 11K | $72K |
| Aug 16, 2019 | Hughes Steven George | Chief Medical Officer | Sell (S) | 22K | $6K |
| Nov 8, 2018 | Presnell Sharon Collins | Chief Scientific Officer | Sell (S) | 40K | $51K |
| Nov 24, 2017 | Murphy Keith | Insider | Buy (P) | 201K | $299K |
| Nov 22, 2017 | Murphy Keith | Insider | Buy (P) | 135K | $203K |
| Feb 9, 2017 | Murphy Keith | Chairman, CEO and President, Director | Sell (S) | 25K | $92K |
| Jan 24, 2017 | Murphy Keith | Chairman, CEO and President, Director | Sell (S) | 20K | $70K |
| Jan 23, 2017 | Murphy Keith | Chairman, CEO and President, Director | Sell (S) | 5K | $17K |
| Dec 14, 2016 | Murphy Keith | Chairman, CEO and President, Director | Sell (S) | 50K | $186K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 4 | 3 | – |
Insiders Form 4 open-market | 1 | 0 | +$3K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for VIVS
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/VIVS/capital-change-brief"
Use Arkolith's capital_change_brief for VIVS. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for VIVS. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.